These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 9134631)
41. Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. de Paula Sabino A; Ribeiro DD; Carvalho Md; Cardoso J; Dusse LM; Fernandes AP Blood Coagul Fibrinolysis; 2006 Jun; 17(4):271-5. PubMed ID: 16651869 [TBL] [Abstract][Full Text] [Related]
42. Evaluation of thrombotic children with malignancy. Unal S; Varan A; Yalçin B; Büyükpamukçu M; Gürgey A Ann Hematol; 2005 Jun; 84(6):395-9. PubMed ID: 15735962 [TBL] [Abstract][Full Text] [Related]
43. Minor events and the risk of deep venous thrombosis. Eekhoff EM; Rosendaal FR; Vandenbroucke JP Thromb Haemost; 2000 Mar; 83(3):408-11. PubMed ID: 10744145 [TBL] [Abstract][Full Text] [Related]
44. Frequency of factor V Arg506 Gln in Italians. Mannucci PM; Duca F; Peyvandi F; Tagliabue L; Merati G; Martinelli I; Cattaneo M Thromb Haemost; 1996 Apr; 75(4):694. PubMed ID: 8743202 [No Abstract] [Full Text] [Related]
45. Factor V Arg506-->Gln mutation in patients with antiphospholipid antibodies. Montaruli B; Borchiellini A; Tamponi G; Giorda L; Bessone P; van Mourik JA; Voorberg J; Schinco P Lupus; 1996 Aug; 5(4):303-6. PubMed ID: 8869903 [TBL] [Abstract][Full Text] [Related]
46. Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506 -->Gln mutation. Biousse V; Piette JC; Frances C; Bletry O; Papo T; Tournier-Lasserve E; Duchemin J; Aiach M J Rheumatol; 1995 Jun; 22(6):1215. PubMed ID: 7674266 [No Abstract] [Full Text] [Related]
47. Homozygous factor V Leiden mutation in two siblings presenting with acute myocardial infarction: a rare cause of myocardial infarction in the young. Kaykçoğlu M; Hasdemir C; Eroğlu Z; Kosova B; Can LH; Ildizli M; Yavuzgil O; Payzin S; Turkoglu C Blood Coagul Fibrinolysis; 2005 Jun; 16(4):281-6. PubMed ID: 15870548 [TBL] [Abstract][Full Text] [Related]
48. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Zama T; Murata M; Ono F; Watanabe K; Watanabe R; Moriki T; Yokoyama K; Tokuhira M; Ikeda Y Int J Hematol; 1996 Dec; 65(1):71-8. PubMed ID: 8990627 [TBL] [Abstract][Full Text] [Related]
49. Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation. Le Cam-Duchez V; Gandrille S; Trégouët D; Alhenc-Gelas M; Emmerich J; Fiessinger JN; Borg JY; Aiach M Br J Haematol; 1999 Sep; 106(4):889-97. PubMed ID: 10519989 [TBL] [Abstract][Full Text] [Related]
50. Apparent heterozygous type II protein C deficiency caused by the factor V 506 Arg to Gln mutation. Ireland H; Bayston T; Thompson E; Adami A; Gonçalves C; Lane DA; Finazzi G; Barbui T Thromb Haemost; 1995 Apr; 73(4):731-2. PubMed ID: 7495091 [No Abstract] [Full Text] [Related]
51. Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Chowdhury V; Lane DA; Mille B; Auberger K; Gandenberger-Bachem S; Pabinger I; Olds RJ; Thein SL Thromb Haemost; 1994 Aug; 72(2):198-202. PubMed ID: 7831651 [TBL] [Abstract][Full Text] [Related]
52. Plasminogen deficiency: an additional risk factor for thrombosis in a family with factor V R506Q mutation? Züger M; Biasiutti FD; Furlan M; Mannhalter C; Lämmle B Thromb Haemost; 1996 Sep; 76(3):475-6. PubMed ID: 8883289 [No Abstract] [Full Text] [Related]
53. Resistance to activated protein C and Arg 506 Gln factor V mutation are uncommon in eastern Asian populations. Kodaira H; Ishida F; Shimodaira S; Takamiya O; Furihata K; Kitano K Acta Haematol; 1997; 98(1):22-5. PubMed ID: 9210909 [TBL] [Abstract][Full Text] [Related]
54. Portal vein thrombosis and factor V Arg 506 to Gln mutation. Levoir D; Emmerich J; Alhenc-Gelas M; Dumontier I; Petite JP; Fiessinger JN; Aiach M Thromb Haemost; 1995 Mar; 73(3):550-1. PubMed ID: 7667842 [No Abstract] [Full Text] [Related]
55. Mutation in the factor V gene and the risk of myocardial infarction. Heinrich J; Budde T; Assmann G N Engl J Med; 1995 Sep; 333(13):881. PubMed ID: 7651495 [No Abstract] [Full Text] [Related]
56. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Press RD; Liu XY; Beamer N; Coull BM Stroke; 1996 Jan; 27(1):44-8. PubMed ID: 8553401 [TBL] [Abstract][Full Text] [Related]
57. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Emmerich J; Poirier O; Evans A; Marques-Vidal P; Arveiler D; Luc G; Aiach M; Cambien F Lancet; 1995 Feb; 345(8945):321. PubMed ID: 7837881 [No Abstract] [Full Text] [Related]
58. Leiden factor V mutation in four patients with small bowel infarctions. Heresbach D; Pagenault M; Gueret P; Crenn P; Heresbach-Le Berre N; Malledant Y; Fauchet R; Horellou MH; Silver J; Messing B; Bretagne JF Gastroenterology; 1997 Jul; 113(1):322-5. PubMed ID: 9207293 [TBL] [Abstract][Full Text] [Related]
59. Specificity of an assay based on a factor V-depleted plasma in patients carrying the Arg 506 Gln mutation. Alhenc-Gelas M; Aillaud MF; Bonvarlet MN; Dupuy G; Juhan-Vague I; Aiach M Thromb Haemost; 1996 Jun; 75(6):976-7. PubMed ID: 8822599 [No Abstract] [Full Text] [Related]
60. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. Gandrille S; Greengard JS; Alhenc-Gelas M; Juhan-Vague I; Abgrall JF; Jude B; Griffin JH; Aiach M Blood; 1995 Jul; 86(1):219-24. PubMed ID: 7795227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]